UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                    Washington, D.  C.  20549

                           FORM 10-QSB


[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
    OF 1934

            For quarterly period ended:  June 30, 2002

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934


                  Commission File No.  000-30991

             SKINOVATION PHARMACEUTICAL INCORPORATED
   (Name of small business issuer as specified in its charter)


         NEVADA                                          87-0458170
(State of incorporation)               (I. R. S. Employer Identification No.)

                      2157 S. Lincoln Street
                    Salt Lake City, Utah 84106
                          (801) 323-2395
  (Address and telephone number of principal executive offices)

                        525 South 300 East
                    Salt Lake City, Utah 84111
                         (Former address)

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes [X]   No [ ]

As of August 5, 2002, the issuer had a total of 708,000 shares of common stock
issued and outstanding.

<PAGE> 1

                 PART I:   FINANCIAL INFORMATION


ITEM 1: FINANCIAL STATEMENTS

      The financial information set forth below with respect to our statements
of operations for the three and six month periods ended June 30, 2002 and 2001
is unaudited.  This financial information, in the opinion of management,
includes all adjustments consisting of normal recurring entries necessary for
the fair presentation of such data.  The results of operations for the three
and six months ended June 30, 2002, are not necessarily indicative of results
to be expected for any subsequent period.


<PAGE> 2








                 Skinovation Pharmaceutical, Inc.
                       Financial Statements
                          June 30, 2002



<PAGE> 3




                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                          Balance Sheets



                              ASSETS

                                                     June 30,    December 31,
                                                       2002         2001
                                                  ------------- -------------
                                                   (Unaudited)

CURRENT ASSETS                                    $          -  $          -
                                                  ------------- -------------

  TOTAL ASSETS                                    $          -  $          -
                                                  ============= =============


               LIABILITIES AND STOCKHOLDER' EQUITY

CURRENT LIABILITIES

Accounts Payable - Related party                  $     28,776  $     28,776
                                                  ------------- -------------

  Total Liabilities                                     28,776        28,776
                                                  ------------- -------------
STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 50,000,000
  shares authorized; 708,000 shares
  issued and outstanding                                   708           708

Additional Paid in Capital                              25,148        25,148

Deficit Accumulated During the Development Stage       (54,632)      (54,632)
                                                  ------------- -------------

  Total Stockholders' Equity                           (28,776)      (28,776)
                                                  ------------- -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $          -  $          -
                                                  ============= =============


<PAGE> 4
<TABLE>
<CAPTION>



                         Skinovation Pharmaceutical, Inc.
                           (A Development Stage Company)
                              Statement of Operations
                                    (Unaudited)


                                                                                            From
                                                                                            inception on
                                For the        For the        For the        For the        January 15,
                                three months   three months   six months     six months     1988
                                ended June 30, ended June 30, ended June 30, ended June 30, to June 30,
                                2002           2001           2002           2001           2002
                                -------------- -------------- -------------- -------------- -------------

                             <c>            <c>            <c>            <c>            <c>
REVENUES                        $           -  $           -  $           -  $           -  $     27,937
                                -------------- -------------- -------------- -------------- -------------
EXPENSES

  General & Administrative                  -              -              -              -       119,644
                                -------------- -------------- -------------- -------------- -------------

    TOTAL EXPENSES                          -              -              -              -       119,644
                                -------------- -------------- -------------- -------------- -------------
NET LOSS BEFORE DISCONTINUED
  OPERATIONS                                -              -              -              -       (91,707)

GAIN ON DISPOSAL OF OPERATIONS              -              -              -              -        37,075
                                -------------- -------------- -------------- -------------- -------------

NET INCOME (LOSS)               $           -  $           -  $           -  $           -  $    (54,632)
                                ============== ============== ============== ============== =============

NET LOSS PER SHARE              $           -  $           -  $           -  $           -  $      (0.12)
                                ============== ============== ============== ============== =============
WEIGHTED AVERAGE SHARES
  OUTSTANDING                         708,000        708,000        708,000        708,000       533,610
                                ============== ============== ============== ============== =============

</TABLE>
<PAGE> 5
<TABLE>
<CAPTION>

                         Skinovation Pharmaceutical, Inc.
                           (A Development Stage Company)
                              Statement of Cash Flows
                                    (Unaudited)


                                                                                          From
                                                                                          Inception on
                                                             For the six months ended     January 15, 1988
                                                                      June 30,            Through
                                                                 2002           2001      June 30, 2002
                                                             ------------- -------------- --------------
<S>                                                          <C>           <C>            <C>
Cash Flows from Operating Activities

  Net Loss                                                   $          -  $           -  $     (54,632)
  Less  Non-cash Items:
   Shares issued for services                                           -              -         10,433
   Shares issued for debt payment                                       -              -          1,424
   Increase in accounts payable                                         -              -         28,776
   Loss on disposal of PP&E                                             -              -          5,263
                                                             ------------- -------------- --------------

  Net Cash Provided (Used) by Operating Activities                      -              -         (8,736)
                                                             ------------- -------------- --------------
Cash Flows from Investing Activities
  Cash paid for PP&E                                                    -              -         (5,264)
                                                             ------------- -------------- --------------

  Net Cash Provided (Used) by Investing Activities                      -              -         (5,264)
                                                             ------------- -------------- --------------
Cash Flows from Financing Activities
  Cash paid for offering costs                                          -              -         (7,000)
  Common stock issued for cash                                          -              -         21,000
                                                             ------------- -------------- --------------

  Net Cash Provided (Used) by Financing Activities                      -              -         14,000
                                                             ------------- -------------- --------------

Increase (Decrease) in Cash                                             -              -              -

Cash and Cash Equivalents at Beginning of Period                        -              -              -
                                                             ------------- -------------- --------------

Cash and Cash Equivalents at End of Period                   $          -  $           -  $           -
                                                             ============= ============== ==============

Supplemental Cash Flow Information:
  Stock issued for debt payment                              $          -  $           -  $       1,424
  Stock issued for services                                  $          -  $           -  $      10,433
  Cash Paid For:
    Interest                                                 $          -  $           -  $           -
    Income Taxes                                             $          -  $           -  $           -

</TABLE>
<PAGE> 6


                 Skinovation Pharmaceutical, Inc.
                  (A Development Stage Company)
                Notes to the Financial Statements
                          June 30, 2002


GENERAL

Skinovation Pharmaceutical, Inc.  (the Company) has elected to omit
substantially all footnotes to the financial statements for the six months
ended June 30, 2002 since there have been no material changes (other than
indicated in other footnotes) to the information previously reported by the
Company in their Annual Report filed on the Form 10-KSB for the twelve months
ended December 31, 2001.

UNAUDITED INFORMATION

The information furnished herein was taken from the books and records of the
Company without audit.  However, such information reflects all adjustments
which are, in the opinion of management, necessary to properly reflect the
results of the interim period presented.  The information presented is not
necessarily indicative of the results from operations expected for the full
fiscal year.




<PAGE> 7


     In this report references to "Skinovation," "we," "us," and "our" refer
to Skinovation Pharmaceutical Incorporated.

                    Forward Looking Statements

     This Form 10-QSB contains certain forward-looking statements and any
statements contained in this Form 10-QSB that are not statements of historical
fact may be deemed to be forward-looking statements.  Without limiting the
foregoing, words such as "may," "will," "expect," "believe," "anticipate,"
"estimate" or "continue" or comparable terminology are intended to identify
forward-looking statements.  These statements by their nature involve
substantial risks and uncertainties, and actual results may differ materially
depending on a variety of factors, many of which are not within Skinovation's
control.  These factors include but are not limited to economic conditions
generally and in the market which Skinovation may participate; competition
within Skinovation's chosen market and failure by Skinovation to successfully
develop business relationships.

ITEM 2:  PLAN OF OPERATIONS

     We are a development stage company with no assets, we have experienced
losses since our inception and we are dependent on financing to continue our
operations.  For the six month period ended June 30, 2002, we had no cash on
hand and total current liabilities of $28,776.  The $28,766 account payable is
related to accounting and legal fees paid on our behalf by a related party in
fiscal year 1999.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
may be met by loans from our directors, officers and stockholders.  However,
these understandings are not formal agreements and therefore these persons are
not obligated to provide funds.  We may repay any loans, costs of services and
advancements with cash, if available, or we may convert them into common
stock.

     Our management intends to actively pursue business opportunities during
the next twelve months.  Based on current economic and regulatory conditions,
management believes that it is possible, if not probable, for a company like
ours, without many assets or liabilities, to negotiate a merger or acquisition
with a viable private company.  The opportunity arises principally because of
the high legal and accounting fees and the length of time associated with the
registration process of "going public."  However, should any of these
conditions change, it is very possible that there would be little or no
economic value for anyone taking over control of Skinovation. In addition, we
have not made a formal study of the economic potential of any business.  At
the date of this filing, we have not identified any assets or business
opportunities for acquisition.

     All risks inherent in new and inexperienced enterprises are inherent in
our business.  Potential investors must recognize that because of our limited
capital available for investigation and management's limited experience in
business analysis we may not discover or adequately evaluate adverse facts
about the business opportunity to be acquired.  Also, we intend to concentrate
our acquisition efforts on properties or businesses that we believe to be
undervalued or that we believe may realize a substantial benefit from being
publicly owned.  Investors should expect that any acquisition candidate may
have little or no operating history, or a history of losses or low
profitability.

     It is emphasized that our management may effect transactions having a
potentially adverse impact upon our shareholders pursuant to the authority and
discretion of our management to complete acquisitions without submitting any
proposal to the stockholders for their consideration.

     Should a merger or acquisition prove unsuccessful, it is possible that we
may decide not to pursue further acquisition activities and management may
abandon its activities and our shares would become worthless.

<PAGE> 8

                   PART II:  OTHER INFORMATION

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)   Part II Exhibits

3.1   Articles of Incorporation as amended  (Incorporated by reference to
      exhibit 3.1 of the Form 10-KSB, filed March 29, 2002)

3.2   Bylaws of Skinovation (Incorporated by reference to exhibit 3.3 of the
      Form-SB, filed July 11, 2000)


(b)   Reports on Form 8-K

      None.



                            SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.


                                  Skinovation Pharmaceutical Incorporated


     8/8/02                            /s/ John W. Peters
Date_________________________   By: ____________________________________
                                    John W. Peters
                                    President, Principal Financial and
                                    Accounting Officer, and Director




                                9